DCTH Stock Overview
An interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Delcath Systems, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.70 |
| 52 Week High | US$9.18 |
| 52 Week Low | US$2.25 |
| Beta | 0.64 |
| 11 Month Change | 4.69% |
| 3 Month Change | 64.15% |
| 1 Year Change | 96.39% |
| 33 Year Change | -11.94% |
| 5 Year Change | -83.18% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Is Delcath Systems (NASDAQ:DCTH) Using Debt In A Risky Way?
Jan 15
Delcath Systems (NASDAQ:DCTH) Has Debt But No Earnings; Should You Worry?
Oct 04Delcath Systems Q2 2022 Earnings Preview
Aug 05Delcath Systems to raise $5M in stock and warrants offering
Jul 18Delcath Systems: Revisiting A $5 Lottery Ticket
May 17Is Delcath Systems (NASDAQ:DCTH) Weighed On By Its Debt Load?
Mar 24Does Delcath Systems (NASDAQ:DCTH) Have A Healthy Balance Sheet?
Nov 17Diving Into Delcath Systems
Aug 09Delcath Systems: Ready To Return To A Previous Winner
Jun 22Delcath Systems set to join Russell Microcap Index
Jun 08Shareholder Returns
| DCTH | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 17.1% | 0.7% | -2.9% |
| 1Y | 96.4% | -1.2% | 17.2% |
Return vs Industry: DCTH exceeded the US Medical Equipment industry which returned -1.1% over the past year.
Return vs Market: DCTH exceeded the US Market which returned 19.8% over the past year.
Price Volatility
| DCTH volatility | |
|---|---|
| DCTH Average Weekly Movement | 11.6% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: DCTH's share price has been volatile over the past 3 months.
Volatility Over Time: DCTH's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 76 | Gerard Michel | www.delcath.com |
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma.
Delcath Systems, Inc. Fundamentals Summary
| DCTH fundamental statistics | |
|---|---|
| Market cap | US$245.63m |
| Earnings (TTM) | -US$49.79m |
| Revenue (TTM) | US$4.61m |
52.5x
P/S Ratio-4.9x
P/E RatioIs DCTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DCTH income statement (TTM) | |
|---|---|
| Revenue | US$4.61m |
| Cost of Revenue | US$1.36m |
| Gross Profit | US$3.25m |
| Other Expenses | US$53.04m |
| Earnings | -US$49.79m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 05, 2024
| Earnings per share (EPS) | -1.79 |
| Gross Margin | 70.54% |
| Net Profit Margin | -1,080.73% |
| Debt/Equity Ratio | 50.3% |
How did DCTH perform over the long term?
See historical performance and comparison